Trevi Therapeutics (NASDAQ:TRVI) focuses on developing treatments for serious conditions related to chronic cough and pruritus by leveraging its expertise in neuroscience. The company is pioneering with Haduvio™ (nalbuphine ER), aiming to address the unmet medical needs in these areas. Trevi Therapeutics is committed to improving the quality of life for patients struggling with debilitating symptoms by advancing its robust clinical programs and exploring new therapeutic avenues. Their objective is not just to innovate within the therapeutic landscape but also to ensure these advancements are accessible to those in need, effectively bridging the gap between groundbreaking research and patient care.